Know Cancer

forgot password

Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma

Phase 2
18 Years
Not Enrolling
Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms

Thank you

Trial Information

Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma

Inclusion Criteria:

- ≥ 18 years old

- Histologically confirmed renal cell carcinoma with clinically or pathologically
confirmed progression

- Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior

- Measurable disease

- Hemoglobin ≥ 9 mg/dL

- ECOG performance status of 0, 1, or 2

- Willing and able to provide written informed consent

Exclusion Criteria:

- Inadequate bone marrow, renal and liver function by laboratory criteria

- Absolute neutrophil count < 1500/µL;

- Platelet count < 100,000/µL;

- AST or ALT > 2 x upper limit of normal (ULN);

- Alkaline phosphatase > 5 x ULN;

- Total bilirubin > 2 x ULN;

- Creatinine > 2.0 mg/dL.

- Evidence of central nervous system metastases within past year

- Uncontrolled hypertension

- Known history of porphyria, G6PD deficiency or HIV

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Clinical response rate (CP, PR) to MGd in patients with confirmed progressive RCC (renal cell carcinoma)

Principal Investigator

Robert J Amato, D.O.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Methodist Hospital Genitourinary Oncology


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Carcinoma, Renal Cell
  • Urogenital Neoplasms
  • Urologic Neoplasms
  • Kidney Neoplasms
  • Kidney cancer
  • Renal cell carcinoma
  • Motexafin gadolinium
  • Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Urogenital Neoplasms
  • Urologic Neoplasms



Methodist Hospital Houston, Texas  77030